User login
Lupus nephritis is a serious complication of lupus for which there is a great unmet therapeutic need. The first step to preserve kidney function is to identify kidney involvement with blood and urine tests, and to assess whether a kidney biopsy is needed. Dr. Richard Furie, Chief of Rheumatology at Northwell Health, shares recommendations for evaluating whether a patient is a candidate for kidney biopsy based on their protein/creatinine ratio and serologic activity.
Dr. Furie also reviews treatment options based on biopsy results, including steroids, immunosuppressive agents, and calcineurin inhibitors, as well as significant findings from the recent BLISS-LN, NOBILITY, and AURORA trials.
--
Chief of Rheumatology, Northwell Health
Professor, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Feinstein Institutes for Medical Research
Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Richard A. Furie, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
Received income in an amount equal to or greater than $250 from AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
Lupus nephritis is a serious complication of lupus for which there is a great unmet therapeutic need. The first step to preserve kidney function is to identify kidney involvement with blood and urine tests, and to assess whether a kidney biopsy is needed. Dr. Richard Furie, Chief of Rheumatology at Northwell Health, shares recommendations for evaluating whether a patient is a candidate for kidney biopsy based on their protein/creatinine ratio and serologic activity.
Dr. Furie also reviews treatment options based on biopsy results, including steroids, immunosuppressive agents, and calcineurin inhibitors, as well as significant findings from the recent BLISS-LN, NOBILITY, and AURORA trials.
--
Chief of Rheumatology, Northwell Health
Professor, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Feinstein Institutes for Medical Research
Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Richard A. Furie, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
Received income in an amount equal to or greater than $250 from AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
Lupus nephritis is a serious complication of lupus for which there is a great unmet therapeutic need. The first step to preserve kidney function is to identify kidney involvement with blood and urine tests, and to assess whether a kidney biopsy is needed. Dr. Richard Furie, Chief of Rheumatology at Northwell Health, shares recommendations for evaluating whether a patient is a candidate for kidney biopsy based on their protein/creatinine ratio and serologic activity.
Dr. Furie also reviews treatment options based on biopsy results, including steroids, immunosuppressive agents, and calcineurin inhibitors, as well as significant findings from the recent BLISS-LN, NOBILITY, and AURORA trials.
--
Chief of Rheumatology, Northwell Health
Professor, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Feinstein Institutes for Medical Research
Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Richard A. Furie, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
Received income in an amount equal to or greater than $250 from AstraZeneca; GlaxoSmithKline; Genentech; Biogen; Aurinia; Bristol-Myers Squibb; EMD Serono.
